Using its market assessment methodology, DuckerFrontier helped pharmaceutical company Beta determine whether the South Korean healthcare system had the infrastructure and capabilities required for a promising new treatment.
Company Beta anticipated successful completion of clinical trials of a new and innovative drug. While this treatment had the potential to benefit a large number of people, it required advanced healthcare infrastructure capable of early detection and diagnosis of the treated disease, which is traditionally hard to uncover.
To assess whether South Korea’s healthcare system met this prerequisite, Company Beta required an in-depth analysis of the current and projected patient population and a comprehensive examination of local healthcare system infrastructure and capabilities to detect the specific disease in its early stages.
DuckerFrontier’s market assessment approach addressed the challenge from two angles:
By synthesizing qualitative and quantitative results, DuckerFrontier identified local market dynamics, regional access to early detection tests, and the growth trajectory of early detection tests over the next five years. With these insights, DuckerFrontier determined the readiness in South Korea for the upcoming treatment. providing a comprehensive solution tailored to Company Beta’s unique challenges.
DuckerFrontier’s teams are committed to helping executives cut through the noise to find fact-based and innovative was to grow their business. We combine our industry and market expertise with our proven methodologies to provide clients with the highest quality insights and intelligence they need to make strategic decisions in their most important markets. Contact us here to connect with a team member. Don’t miss our latest case studies on partner identification and selection in the medical devices space and global healthcare business unit prioritization.